Article Text

Download PDFPDF
Management of lipid exudates in Coats disease by adjuvant intravitreal triamcinolone: effects and complications
  1. Ihab Saad Othman1,2,
  2. Magdy Moussa3,
  3. Manal Bouhaimed4
  1. 1Department of Ophthalmology -Kasr El-Ainie University Hospital, Cairo University, Cairo, Egypt
  2. 2The Oncology Service, National Eye Center, Rod EL-Farag, Cairo, Egypt
  3. 3Department of Ophthalmology, Tanta University, Tanta, Egypt
  4. 4Departments of Community Medicine and Surgery, Faculty of Medicine, Kuwait University, The State of Kuwait
  1. Correspondence to Dr Ihab Saad Othman, 6 Tahrir Street, Dokki, Giza, Egypt; ihabsaad{at}


Aim To evaluate the role of intravitreal Triamcinolone (TA) in the early management of Coats disease.

Methods Retrospective, interventional case series.

Results 15 consecutive cases with Coats disease were managed with 4 mg/0.1 ml intravitreal TA injection on presentation and were followed for a minimum of 1 year duration. Additional management strategies including drainage of subretinal fluid through an inferior sclerotomy, peripheral laser ablation and/or cryotherapy, cataract extraction and vitrectomy were performed. Improvement of visual acuity could be achieved compared with preoperative vision in all cases in this series, even when 40% needed cataract extraction with intraocular lens implantation. One patient needed antiglaucoma treatment to control raised intraocular pressure in this series.

Conclusions Triamcinolone has a role in improving the rate of absorption of subretinal fluid and macular exudates in Coats disease. The major complication of 4 mg/0.1 ml intravitreal triamcinolone is cataract in 40% of cases in children.

  • Lipid exudates
  • intravitreal triamcinolone injection
  • Coats
  • disease
  • exudative retinal detachment
  • complicated cataract
  • retinal telangiectasia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests None.

  • Patient consent Obtained from the patient's family.

  • Ethics approval Ethics approval was provided by the National Eye Center, Cairo, Egypt.

  • Provenance and peer review Not commissioned; externally peer reviewed.